Hide metadata

dc.date.accessioned2020-09-01T18:13:42Z
dc.date.available2020-09-01T18:13:42Z
dc.date.created2020-08-05T09:01:43Z
dc.date.issued2020
dc.identifier.citationGynnild, Mari Nordbø Aakerøy, Rachel Spigset, Olav Askim, Torunn Beyer, Mona Kristiansen Ihle-Hansen, Hege Munthe-Kaas, Ragnhild Knapskog, Anne Brita Lydersen, Stian Næss, Halvor Røsstad, Tove Garåsen Seljeseth, Yngve Müller Thingstad, Pernille Saltvedt, Ingvild Ellekjær, Hanne . Vascular risk factor control and adherence to secondary preventive medication after ischemic stroke. Journal of Internal Medicine. 2020
dc.identifier.urihttp://hdl.handle.net/10852/79102
dc.description.abstractBackground Studies regarding adequacy of secondary stroke prevention are limited. We report medication adherence, risk factor control and factors influencing vascular risk profile following ischaemic stroke. Methods A total of 664 home‐dwelling participants in the Norwegian Cognitive Impairment After Stroke study, a multicenter observational study, were evaluated 3 and 18 months poststroke. We assessed medication adherence by self‐reporting (4‐item Morisky Medication Adherence Scale) and medication persistence (defined as continuation of medication(s) prescribed at discharge), achievement of guideline‐defined targets of blood pressure (BP) (<140/90 mmHg), low‐density lipoprotein cholesterol (LDL‐C) (<2.0 mmol L−1) and haemoglobin A1c (HbA1c) (≤53 mmol mol−1) and determinants of risk factor control. Results At discharge, 97% were prescribed antithrombotics, 88% lipid‐lowering drugs, 68% antihypertensives and 12% antidiabetic drugs. Persistence of users declined to 99%, 88%, 93% and 95%, respectively, at 18 months. After 3 and 18 months, 80% and 73% reported high adherence. After 3 and 18 months, 40.7% and 47.0% gained BP control, 48.4% and 44.6% achieved LDL‐C control, and 69.2% and 69.5% of diabetic patients achieved HbA1c control. Advanced age was associated with increased LDL‐C control (OR 1.03, 95% CI 1.01 to 1.06) and reduced BP control (OR 0.98, 0.96 to 0.99). Women had poorer LDL‐C control (OR 0.60, 0.37 to 0.98). Polypharmacy was associated with increased LDL‐C control (OR 1.29, 1.18 to 1.41) and reduced HbA1c control (OR 0.76, 0.60 to 0.98). Conclusion Risk factor control is suboptimal despite high medication persistence and adherence. Improved understanding of this complex clinical setting is needed for optimization of secondary preventive strategies.
dc.languageEN
dc.publisherBlackwell Science Ltd.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleVascular risk factor control and adherence to secondary preventive medication after ischemic stroke
dc.typeJournal article
dc.creator.authorGynnild, Mari Nordbø
dc.creator.authorAakerøy, Rachel
dc.creator.authorSpigset, Olav
dc.creator.authorAskim, Torunn
dc.creator.authorBeyer, Mona Kristiansen
dc.creator.authorIhle-Hansen, Hege
dc.creator.authorMunthe-Kaas, Ragnhild
dc.creator.authorKnapskog, Anne Brita
dc.creator.authorLydersen, Stian
dc.creator.authorNæss, Halvor
dc.creator.authorRøsstad, Tove Garåsen
dc.creator.authorSeljeseth, Yngve Müller
dc.creator.authorThingstad, Pernille
dc.creator.authorSaltvedt, Ingvild
dc.creator.authorEllekjær, Hanne
cristin.unitcode185,53,63,0
cristin.unitnameKlinikk for radiologi og nukleærmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin1821682
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Internal Medicine&rft.volume=&rft.spage=&rft.date=2020
dc.identifier.jtitleJournal of Internal Medicine
dc.identifier.doihttps://doi.org/10.1111/joim.13161
dc.identifier.urnURN:NBN:no-82207
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0954-6820
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/79102/1/joim.13161.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International